Treatment for Mild Chronic Hypertension during Pregnancy

Tita, Alan T.N.; Szychowski, Jeff M.; Boggess, Kim; Dugoff, Lorraine; Sibai, Baha M.; Lawrence, Kirsten; Hughes, Brenna L.; Bell, Joseph; Aagaard, Kjersti M.; Edwards, Rodney K.; Gibson, Kelly S.; Haas, David M.; Plante, Lauren A.; Metz, Torri D.; Casey, Brian M.; Esplin, Sean; Longo, Sherri; Hoffman, Matthew R.; Saade, George R.; Hoppe, Kara K.; Foroutan, Janelle; Tuuli, Methodius G.; Owens, Michelle; Simhan, Hyagriv N.; Frey, Heather A.; Rosen, T.John; Palatnik, Anna; Baker, Susan; August, Phyllis; Reddy, Uma M.; Kinzler, Wendy L.; Su, Emily J.; Krishna, Iris; Nguyen, Nicki; Norton, Mary E.; Skupski, Daniel; El‐Sayed, Yasser Y.; Ogunyemi, Dotum; Galis, Zorina S.; Harper, Lorie M.; Ambalavanan, Namasivayam; Geller, Nancy L.; Oparil, Suzanne; Cutter, Gary; Andrews, William

doi:10.1056/nejmoa2201295

Cited by 271 publications

(212 citation statements)

References 24 publications

Supporting

Mentioning

200

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown mixed results with low-sodium diet. The SODIUM-HF trial re-examined the validity of this long-standing recommendation to limit sodium intake in patients with HF [ 1 •].…”

Section: Sodium-hf—the Study Of Dietary Intervention Under 100 Mmol I...mentioning

confidence: 99%

“…The CHAP trial was an open-label randomized control trial involving 70 US centers [ 1 •]. Patients with mild cHTN (SBP 140–159/90–104 mmHg), new or pre-existing singleton pregnancy, and < 23-week gestation were included.…”

Section: Chap Trial—antihypertensive Therapy For Mild Chronic Htn Imp...mentioning

confidence: 99%

“…Several studies have examined SGLT2 inhibitors and their cardiorenal protective effects in managing patients with and without HF in regards to HF hospitalizations and CV mortality. Sotagliflozin is an SGLT1 and SGLT2 inhibitor, affecting glucose absorption in the gastrointestinal tract and kidneys which significantly reduced major adverse CV events (MACE) among HF patients in the SOLOIST-WHF trial [ 1 •]. The SCORED trial evaluated sotagliflozin’s effects on MACE in patients with T2DM and CKD, a population at high risk for HF and ischemic events [ 2 ••].…”

Section: Scored Trial—effect Of Sotagliflozin On CV and Renal Events ...mentioning

confidence: 99%

“…The 2022 American College of Cardiology (ACC) Scientific Sessions featured several notable trials regarding CV disease (CVD) prevention and management. Included studies assessed the impact of a low-sodium diet on heart failure (HF) outcomes (SODIUM-HF); antihypertensive management outcomes of pregnant patients with mild chronic hypertension (cHTN) (CHAP) [ 1 •]; sotagliflozin to treat patients with type 2 diabetes mellitus (T2DM) and renal impairment (SCORED) [ 2 ••]; safety and efficacy of SLN360, a short interfering RNA targeting lipoprotein(a) [LP(a)] concentrations (APOLLO); a supermarket and web-based nutrition intervention for CV risk reduction (SuperWIN); a superiority trial comparing myocardial injury following very mild perioperative hypothermia versus aggressive warming after non-cardiac surgery (PROTECT); and 3-year efficacy outcomes of renal denervation on blood pressure (BP) reduction from the SPYRAL HTN-ON MED pilot study. As with prior publications, the significance and clinical implications of select presentations are discussed [ 3 – 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions

Hermel

Tsai

Dlouhy

et al. 2022

Curr Atheroscler Rep

View full text Add to dashboard Cite

Purpose of Review Focused review highlighting select studies presented at the 2022 American College of Cardiology (ACC) Scientific Sessions. Recent Findings Included studies assessed the impact of a low-sodium diet on heart failure outcomes (SODIUM-HF); outcomes of pregnant patients with chronic hypertension treated with antihypertensive therapies (CHAP); cardiovascular outcomes in patients with type 2 diabetes and renal impairment treated with sotagliflozin (SCORED); a safety and efficacy study investigating SLN360, a short interfering RNA targeting lipoprotein(a) (APOLLO); a supermarket and web-based intervention targeting nutrition for cardiovascular risk reduction (SuperWIN); a superiority trial comparing myocardial injury following very mild perioperative hypothermia versus aggressive warming after non-cardiac surgery (PROTECT); and 3-year efficacy outcomes of renal denervation on blood pressure reduction from the SPYRAL HTN-ON MED pilot study. Summary Research presented at the 2022 ACC Scientific Sessions underscores the new potential and meaningful impact of cardiovascular disease prevention and management interventions.

show abstract

Section: Sodium-hf—the Study Of Dietary Intervention Under 100 Mmol I...mentioning

confidence: 99%

Section: Chap Trial—antihypertensive Therapy For Mild Chronic Htn Imp...mentioning

confidence: 99%

Section: Scored Trial—effect Of Sotagliflozin On CV and Renal Events ...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American College of Cardiology Scientific Sessions

Hermel

Tsai

Dlouhy

et al. 2022

Curr Atheroscler Rep

View full text Add to dashboard Cite

show abstract

“…Systolic BP (sBP) < 130 mmHg within 14 weeks of gestation reduced the risk of developing early-onset superimposed PE in women with chronic hypertension [ 67 ]. The Chronic Hypertension and Pregnancy (CHAP) project also showed that BP control to <140/90 was associated with a reduction in composite adverse outcomes, with no significant increase in small for gestational age infants [ 68 ].…”

Section: Up-to-date Preeclampsia Knowledge; What We Should Know For M...mentioning

confidence: 99%